最新ニュース Hologic (NASDAQ:HOLX) 株価情報

Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Hologic Inc

The <a href="https://www.benzinga.com/topic/fda-0">Food and Drug Administration</a> issued a warning letter to Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), citing violations in the manufacturing and reporting processes for its BioZorb product line.
The letter, addressed to CEO and President Stephen MacMillan, outlines significant compliance concerns that have prompted the company to discontinue the product.
During an <a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hologic-inc-698214-12182024" target="_blank" rel="noreferrer noopener">inspection</a> from July 30 to Sept. 24, 2024, at Hologic&#8217;s Marlborough, Massachusetts, facility, the FDA identified several deficiencies related to the production of BioZorb, a class II implantable radiographic marker.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41554220/hologic-recalls-soft-tissue-marker-device-biozorb-fda-issues-warning-after-almost-400-complaints" rel="noreferrer noopener">Hologic Recalls Soft Tissue Marker Device BioZorb, FDA Issues Warning After Almost 400 Complaints</a>
Key violations included failing to establish adequate design control procedures and maintaining quality system regulations.
The FDA highlighted gaps in design input requirements, verification testing, and validation studies, including the inability to confirm that the BioZorb device appropriately meets its intended use or resorbs in soft tissue.
Complaints of malfunction, including cases where the device did not dissolve for nearly five years, were noted as serious concerns.
Despite discontinuing the BioZorb line, the FDA expressed ongoing safety concerns for patients with implanted devices.
Specific risks include cancer detection interference, radiation treatment complications, and incomplete device resorption. Hologic has yet to address these risks adequately for patients who may require intervention or device removal.
The FDA criticized Hologic&#8217;s corrective and preventive action procedures, citing delayed responses to recurring adverse events such as infections, tissue damage, and device migration.
A spike in complaints reported in 2023 went unaddressed until mid-2024, and the company failed to accurately calculate occurrence rates for adverse events.
The letter also flagged lapses in mandatory reporting of adverse events and corrections. Hologic was cited for failing to submit timely Medical Device Reports and corrections under the required timelines.
The FDA has required Hologic to provide a comprehensive corrective action plan within 15 business days, including documentation of steps to prevent future violations.
Failure to comply may result in regulatory actions such as injunctions, product seizures, or civil penalties.
Price Action: HOLX stock is down 0.11% at $69.89 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43060049/bumbles-big-leadership-change-and-financial-outlook-set-the-stage-for-2025" target="_blank" rel="noreferrer noopener">Bumble&#8217;s Leadership Rewind: Founder Whitney Wolfe Herd To Step Back Into CEO Role</a></li>
</ul>
Photo: Shutterstock

News

Health Care

General

HOLX

FDA Warns Hologic Over BioZorb Manufacturing Violations

Morgan Stanley analyst Tejas Savant maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Equal-Weight and lowers the price target from $84 to $82.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Hologic, Lowers Price Target to $82

Needham analyst Mike Matson reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Buy and maintains $90 price target.

Reiteration

Needham Reiterates Buy on Hologic, Maintains $90 Price Target

<ul>
<li>Revenue of $1,021.8 Million Grows 0.9% --</li>
<li>-- Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance –</li>
<li>– GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges –</li>
</ul>

Reported Earlies, Hologic Reports Preliminary Q1 FY25 Revenue Of $1.02B (+0.9% YoY), EPS Expected Near High-End Of Guidance

Hologic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has risen 38.72% since its last report. The company recently reported that it has 6.15 million shares sold short, which is 4.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734534921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hologic has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 3.76%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Hologic's Recent Short Interest

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/implantable-marker-recall-hologic-removes-biozorb-3d-bioabsorbable-markers-due-risk-patient#:~:text=Medical%20Device%20Recalls-,Implantable%20Marker%20Recall%3A%20Hologic%20Removes%20BioZorb%203D%20Bioabsorbable%20Markers,to%20Risk%20for%20Patient%20Complications&amp;text=This%20recall%20involves%20removing%20devices,you%20continue%20to%20use%20it">https://www.fda.gov/medical-devices/medical-device-recalls/implantable-marker-recall-hologic-removes-biozorb-3d-bioabsorbable-markers-due-risk-patient#:~:text=Medical%20Device%20Recalls-,Implantable%20Marker%20Recall%3A%20Hologic%20Removes%20BioZorb%203D%20Bioabsorbable%20Markers,to%20Risk%20for%20Patient%20Complications&amp;text=This%20recall%20involves%20removing%20devices,you%20continue%20to%20use%20it</a>
&nbsp;
This <a href="https://www.fda.gov/medical-devices/medical-device-recalls/what-medical-device-recall">recall</a> involves removing devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it.
<h2>Affected Product</h2>
<ul>
<li>Product Names: BioZorb Marker and BioZorb LP Marker</li>
<li>Product Codes: NEU</li>
<li>Product Part Numbers:
<ul>
<li>F0405 BioZorb Marker 4cm x 5cm</li>
<li>F0404 BioZorb Marker 4cm x 4cm</li>
<li>F0331 BioZorb Marker 1cm x 3cm x 3cm</li>
<li>F0231 BioZorb Marker 1cm x 3cm x 2cm</li>
<li>F0221 BioZorb Marker 1cm x 3cm x 2cm</li>
<li>F0304 BioZorb Marker 3cm x 4cm</li>
<li>F0303 BioZorb Marker 3cm x 3cm</li>
<li>F0203 BioZorb Marker 2cm x 3cm</li>
<li>F0202 BioZorb Marker 2cm x 2cm</li>
</ul>
</li>
<li>Product Description and UDI:
<ul>
<li><a href="https://www.fda.gov/medical-devices/medical-device-recalls/implantable-marker-recall-hologic-removes-biozorb-3d-bioabsorbable-markers-due-risk-patient#devices">See full list of affected devices</a>.</li>
</ul>
</li>
<li>Lot numbers: All unused lot numbers</li>
</ul>
<h2>What to Do</h2>
<ul>
<li>Do not use BioZorb Marker and BioZorb LP Marker.</li>
<li>Monitor patients who have an implanted BioZorb Marker for signs of any adverse events.</li>
</ul>
On October 24, 2024, Hologic sent all affected customers an Urgent Medical Device Recall letter recommending the following actions:
<h3>For Patients</h3>
<ul>
<li>Be aware that there is no need to have the BioZorb Marker removed from your body (explanted), unless your health care provider says otherwise.</li>
<li>Contact your health care provider if you experience any adverse events after you receive a BioZorb Marker.</li>
<li>Report any problems or complications with your BioZorb Marker to the FDA.</li>
<li>Discuss possible risks with a health care provider if you have a BioZorb Marker and/or the provider plans radiation therapy treatment.</li>
</ul>
<h3>For Health Care Providers</h3>
<ul>
<li>Do not implant BioZorb Markers</li>
<li>Be aware of reports of serious adverse events after placement of BioZorb Marker devices in breast tissue.</li>
<li>Monitor patients who have an implanted BioZorb Marker for signs of any adverse events.</li>
<li>Be aware the FDA has not cleared or approved the use of BioZorb Markers to fill space in the tissue or to improve cosmetic outcomes after procedures, or as a marker for radiation treatment.</li>
<li><a href="https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#report">Report any problems, complaints or complications</a> experienced by patients after the placement of BioZorb Marker devices to the FDA.</li>
</ul>
<h3>For Facilities</h3>
<ul>
<li>Quarantine all products.</li>
<li>Share the notification with all surgeons who have used or plan to use the BioZorb Marker.</li>
<li>Identify product inventory affected by this action.
<ul>
<li>See the Customer Response Form Instructions included with the letter to identify affected products.</li>
</ul>
</li>
<li>Confirm receipt of this communication by completing the online Customer Response Form even if there is no affected product in inventory.
<ul>
<li>Hologic will issue a Return Goods Authorization upon receipt of the Customer Response Form and will arrange for return of all affected products to the firm.</li>
</ul>
</li>
<li>Forward a copy of the notice to other facilities or users who may have received affected product.</li>
</ul>
<h2>Reason for Recall</h2>
Hologic, Inc. is recalling Biozorb Marker due to complications and adverse events reported with implanted devices.
The use of affected product may cause serious adverse health consequences, including pain, infection, rash, device moving from where it was placed (migration), device breaking through the skin (erosion), fluid buildup under the skin (seroma), other complications and/or additional medical treatments, and death.
There have been 252 reported injuries. There have been no reports of death.
<h2>Device Use</h2>
The BioZorb Marker made by Hologic (previously Focal Therapeutics), is an implantable radiographic marker used to mark soft tissues (such as breast tissue) for future medical procedures.
The device has two components: a permanent component which is made of titanium metal and a resorbable component which is made of a plastic material that is intended to be resorbed in the body after 1 year or longer. It is meant for one-time use.
<h2>Contact Information</h2>
Customers in the U.S. with questions about this recall should contact Hologic at <a href="mailto:breasthealth.support@hologic.com">breasthealth.support@hologic.com</a>.

Biotech

FDA Announces Implantable Marker Recall: Hologic Removes BioZorb 3D Bioabsorbable Markers Due To Risk For Patient Complications

Hologic Entered Agreement With The CDC To Develop Analyte Specific Reagents  Of Tests To Aid In H5N1 Bird Flu Detection

Wolfe Research analyst Doug Schenkel initiates coverage on Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Hologic with Peer Perform Rating

Hologic, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) a global leader in women's health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening:
"Today's recommendations are an important acknowledgement of the role of Pap testing combined with HPV testing, which is the gold standard of care and the most effective method of identifying cervical cancer," said Jennifer Schneiders, PhD, President, Diagnostic Solutions at Hologic. "Eliminating cervical cancer is within our reach and history has shown us that safeguarding the most comprehensive screening available is critical to that effort."
Once the leading cause of cancer death in women, cervical cancer mortality rates have plummeted by 70% mainly due to cervical cancer screening.1 Despite this progress, cervical cancer incidence is no longer declining and cases continue to disproportionately impact Black and Hispanic women, making a focus on routine screening and vaccination imperative.2-4
Multiple studies and other research representative of real-world screening practices in the US demonstrate that screening women ages 30-65 with the Pap test combined with HPV test identifies more cervical pre-cancer and cancer than either test used alone.5-8 The draft recommendations reinforce the value of all three cervical cancer screening strategies for women including Pap testing for women ages 21-29 years old.9 The draft recommendations also continue to allow for shared decision-making between healthcare providers and patients and help ensure that women can continue to access the preventive care they need and deserve.
Hologic is committed to working with USPSTF and others within the cervical cancer community in support of final screening guidelines that preserve all screening options, improving our ability to combat this preventable cancer and save more women's lives.

Hologic Statement On USPSTF Draft Cervical Cancer Screening Guidelines Committed To Working With USPSTF And Others Within The Cervical Cancer Community In Support Of Final Screening Guidelines That Preserve All Screening Options

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Tycho Peterson initiated coverage on Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Hold rating and announced a price target of $85. Hologic shares closed at $75.79 on Monday. <a href="https://www.benzinga.com/quote/HOLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Heiko Ihle initiated coverage on United States Antimony Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#AMEX">UAMY</a>) with a Buy rating and announced a price target of $2.5. United States Antimony shares closed at $1.62 on Monday. <a href="https://www.benzinga.com/quote/UAMY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM analyst Rohit Kulkarni initiated coverage on Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) with a Buy rating and announced a price target of $4. Rezolve AI shares closed at $1.95 on Monday. See how other analysts view this stock.</li>
<li>JP Morgan analyst Michael Cho initiated coverage on Stifel Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) with a Neutral rating and announced a price target of $120. Stifel Financial shares closed at $110.98 on Monday. <a href="https://www.benzinga.com/quote/SF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Keith Hughes initiated coverage on James Hardie Industries plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) with a Buy rating and announced a price target of $45. James Hardie shares closed at $35.35 on Monday. <a href="https://www.benzinga.com/quote/JHX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying JHX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10074940/image-77-1024x622.png" alt="" class="wp-image-685106" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10074940/image-77-1024x622.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10074940/image-77-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10074940/image-77-768x467.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10074940/image-77.png 1081w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42405361/sp-500-nasdaq-retreat-from-record-highs-investor-sentiment-declines-fear-greed-index-remains-in-neutral-zone">S&amp;P 500, Nasdaq Retreat From Record Highs As Nvidia Declines Over Chinese Antitrust Concerns: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

RZLV

UAMY

This James Hardie Industries Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

12 analysts have shared their evaluations of Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $88.92, a high estimate of $95.00, and a low estimate of $82.00. This current average reflects an increase of 0.01% from the previous average price target of $88.91. 
<img src="https://www.benzinga.com/files/images/story/2024/1733832036_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Hologic's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$89.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$82.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hologic. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hologic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hologic analyst ratings.</a>
<h2>Unveiling the Story Behind Hologic</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Financial Insights: Hologic</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Hologic's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4.52%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 18.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Hologic's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.54%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Hologic's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.98%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Hologic

Jefferies analyst Tycho Peterson initiates coverage on Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Hold rating and announces Price Target of $85.

Jefferies Initiates Coverage On Hologic with Hold Rating, Announces Price Target of $85

Hologic Presented New Research Demonstrating The Performance Of Its Genius AI Detection 2.0 Software Across Diverse Patient Populations At The Scientific Assembly And Annual Meeting Of The Radiological Society Of North America

Hologic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has fallen 5.41% since its last report. The company recently reported that it has 4.59 million shares sold short, which is 2.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732733111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hologic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 3.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Hologic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has risen 5.03% since its last report. The company recently reported that it has 5.81 million shares sold short, which is 3.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730909726_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hologic has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 4.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Hologic's Recent Short Interest

Raymond James analyst Andrew Cooper maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and raises the price target from $93 to $95.

Raymond James Maintains Outperform on Hologic, Raises Price Target to $95

Mizuho analyst Anthony Petrone maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and lowers the price target from $90 to $87.

Mizuho Maintains Outperform on Hologic, Lowers Price Target to $87

UBS analyst Elizabeth Garcia maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Neutral and raises the price target from $84 to $90.

UBS Maintains Neutral on Hologic, Raises Price Target to $90

RBC Capital analyst Conor McNamara maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and raises the price target from $86 to $89.

RBC Capital Maintains Sector Perform on Hologic, Raises Price Target to $89

Evercore ISI lowered the firm's price target on Hologic (HOLX) to $76 from $81 and keeps an In Line rating on the shares. In the firm's 2025 outloo...

Hologic price target lowered to $76 from $81 at Evercore ISI

Hologic ( ($HOLX) ) just unveiled an announcement. Hologic announced that Sally W. Crawford will retire from its Board of Directors, and Scott T. G...

Hologic Announces Board of Directors Changes

"Our fiscal Q1 revenue finished in line with our guidance on a constant currency basis, as the strengthening of the U.S. dollar reduced revenue by ...

Hologic reports preliminary Q1 revenue $1.022B, consensus $1.03B

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hologic (HOLX – Research Report) and Arcutis Bioth...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Hologic (HOLX) and Arcutis Biotherapeutics (ARQT)

In a report released yesterday, Patrick B Donnelly from Citi maintained a Hold rating on Hologic (HOLX – Research Report), with a price target of $...

Hologic: Hold Rating Amid Mixed Financial Performance and Market Conditions

Hologic says Q1 EPS expected to be near high end of guidance ranges

Bank of America Securities analyst Michael Ryskin has maintained their neutral stance on HOLX stock, giving a Hold rating yesterday. Michael Ryskin...

Neutral Rating for Hologic Amid Mixed Segment Performance and Fair Valuation

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Hologic (HOLX – Research Report), with a price target of $...

Morgan Stanley Sticks to Their Hold Rating for Hologic (HOLX)

RBC Capital analyst Conor McNamara maintained a Hold rating on Hologic (HOLX – Research Report) on January 10 and set a price target of $89.00. The...

RBC Capital Reaffirms Their Hold Rating on Hologic (HOLX)

Hologic: Reasonably, But Not Compellingly Valued

ARQT

Press Releases

Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024

Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations

New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence

Comments

Hologic

ニュース

最新ニュース Hologic (NASDAQ:HOLX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル